{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=83",
    "query": {
      "intervention": "Placebo Intravenous",
      "page": 83
    },
    "page_size": 10
  },
  "pagination": {
    "page": 83,
    "page_size": 10,
    "total_count": 2348,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=84&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=82&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:15:09.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06742190",
      "title": "A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multifocal Motor Neuropathy (MMN)",
        "MMN"
      ],
      "interventions": [
        {
          "name": "Empasiprubart",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IVIG (Intravenous Immunoglobulin)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Empasiprubart-placebo",
          "type": "OTHER"
        },
        {
          "name": "IVIg-placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2024-12-18",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 24,
      "location_summary": "Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06742190"
    },
    {
      "nct_id": "NCT01415427",
      "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis IV A",
        "Morquio A Syndrome",
        "MPS IVA"
      ],
      "interventions": [
        {
          "name": "BMN 110 - Weekly",
          "type": "DRUG"
        },
        {
          "name": "BMN 110 - Every Other Week",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2011-07",
      "completion_date": "2016-06-16",
      "has_results": true,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Oakland, California • Orange, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415427"
    },
    {
      "nct_id": "NCT06181786",
      "title": "Study of NAV-240 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "NAV-240",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navigator Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-11-22",
      "completion_date": "2024-09-04",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06181786"
    },
    {
      "nct_id": "NCT06863467",
      "title": "Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic",
        "Chronic Kidney Disease stage3",
        "Chronic Kidney Disease stage4"
      ],
      "interventions": [
        {
          "name": "Intravenous Gemini",
          "type": "DRUG"
        },
        {
          "name": "Intravenous placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revelation Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-01-20",
      "completion_date": "2025-07-22",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • La Mesa, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06863467"
    },
    {
      "nct_id": "NCT02697292",
      "title": "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autoimmune Epilepsy"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-02",
      "completion_date": "2018-12-03",
      "has_results": true,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697292"
    },
    {
      "nct_id": "NCT03027609",
      "title": "Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pseudomonas Aeruginosa Pneumonia"
      ],
      "interventions": [
        {
          "name": "AR-105",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aridis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2017-03-29",
      "completion_date": "2019-04-25",
      "has_results": true,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 14,
      "location_summary": "Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03027609"
    },
    {
      "nct_id": "NCT00940095",
      "title": "Clazosentan in Aneurysmal Subarachnoid Hemorrhage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Clazosentan 5 m/h",
          "type": "DRUG"
        },
        {
          "name": "Clazosentan 15 mg/h",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 577,
      "start_date": "2009-07-01",
      "completion_date": "2011-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 29,
      "location_summary": "Glendale, California • San Francisco, California • Stanford, California + 21 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940095"
    },
    {
      "nct_id": "NCT06305767",
      "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery (RC plus PLND)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2024-03-28",
      "completion_date": "2031-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305767"
    },
    {
      "nct_id": "NCT07038200",
      "title": "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy",
        "FSHD",
        "FSHD - Facioscapulohumeral Muscular Dystrophy",
        "FSHD1",
        "FSHD2",
        "Fascioscapulohumeral Muscular Dystrophy",
        "Fascioscapulohumeral Muscular Dystrophy Type 1",
        "Fascioscapulohumeral Muscular Dystrophy Type 2",
        "Facioscapulohumeral Muscular Dystrophy 1",
        "Facioscapulohumeral Dystrophy",
        "Facio-Scapulo-Humeral Dystrophy",
        "Facioscapulohumeral Muscular Dystrophy 2",
        "Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)",
        "FSH Muscular Dystrophy",
        "Landouzy Dejerine Dystrophy",
        "Landouzy-Dejerine Muscular Dystrophy",
        "Landouzy-Dejerine Syndrome"
      ],
      "interventions": [
        {
          "name": "AOC-1020",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-06-10",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 14,
      "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07038200"
    },
    {
      "nct_id": "NCT03832517",
      "title": "Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety"
      ],
      "interventions": [
        {
          "name": "Single intravenous doses of RC-01",
          "type": "DRUG"
        },
        {
          "name": "Single intravenous doses of placebo",
          "type": "DRUG"
        },
        {
          "name": "Multiple intravenous doses of RC-01",
          "type": "DRUG"
        },
        {
          "name": "Multiple intravenous doses of placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Recida Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 8,
      "start_date": "2019-04-14",
      "completion_date": "2019-05-08",
      "has_results": false,
      "last_update_posted_date": "2019-05-29",
      "last_synced_at": "2026-10-23T10:15:09.357Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03832517"
    }
  ]
}